Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.39
(1.56%)
SEK 0.39
(1.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.22 Million SEK | -10.28% |
| 2022 | -11.99 Million SEK | 67.24% |
| 2021 | -36.61 Million SEK | -265.54% |
| 2020 | -10.01 Million SEK | -305.11% |
| 2019 | -2.47 Million SEK | -13.25% |
| 2018 | -2.18 Million SEK | 16.16% |
| 2017 | -2.6 Million SEK | 63.55% |
| 2016 | -7.14 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.2 Million SEK | -19.89% |
| 2024 Q1 | -6.01 Million SEK | 54.56% |
| 2023 FY | -13.22 Million SEK | -10.28% |
| 2023 Q4 | -13.22 Million SEK | 35.29% |
| 2023 Q2 | -24.75 Million SEK | -362.5% |
| 2023 Q1 | -5.35 Million SEK | 55.38% |
| 2023 Q3 | -20.44 Million SEK | 17.41% |
| 2022 Q2 | -23.2 Million SEK | 28.91% |
| 2022 FY | -11.99 Million SEK | 67.24% |
| 2022 Q4 | -11.99 Million SEK | 25.51% |
| 2022 Q3 | -16.1 Million SEK | 30.61% |
| 2022 Q1 | -32.64 Million SEK | 10.85% |
| 2021 Q1 | -44.03 Million SEK | -339.65% |
| 2021 FY | -36.61 Million SEK | -265.54% |
| 2021 Q3 | -40.44 Million SEK | 3.4% |
| 2021 Q4 | -36.61 Million SEK | 9.46% |
| 2021 Q2 | -41.86 Million SEK | 4.94% |
| 2020 Q2 | -16.17 Million SEK | 29.98% |
| 2020 Q1 | -23.09 Million SEK | -834.15% |
| 2020 Q4 | -10.01 Million SEK | 27.2% |
| 2020 FY | -10.01 Million SEK | -305.11% |
| 2020 Q3 | -13.76 Million SEK | 14.92% |
| 2019 FY | -2.47 Million SEK | -13.25% |
| 2019 Q4 | -2.47 Million SEK | -292.22% |
| 2019 Q1 | 3.03 Million SEK | 238.93% |
| 2019 Q3 | 1.28 Million SEK | 0.0% |
| 2018 Q4 | -2.18 Million SEK | 0.0% |
| 2018 FY | -2.18 Million SEK | 16.16% |
| 2017 FY | -2.6 Million SEK | 63.55% |
| 2016 FY | -7.14 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 73.553% |
| Ziccum AB (publ) | -2.13 Million SEK | -519.054% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 30.592% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.819% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 73.507% |
| Mendus AB (publ) | -96.29 Million SEK | 86.262% |
| Genovis AB (publ.) | -43.94 Million SEK | 69.893% |
| Intervacc AB (publ) | -88.16 Million SEK | 84.994% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 164.501% |
| Active Biotech AB (publ) | -33.2 Million SEK | 60.153% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 124.856% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 66.408% |
| Aptahem AB (publ) | 2.9 Million SEK | 554.823% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 96.035% |
| Kancera AB (publ) | -45.69 Million SEK | 71.047% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 95.98% |
| Fluicell AB (publ) | -2.76 Million SEK | -378.798% |
| Saniona AB (publ) | 40.44 Million SEK | 132.707% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 58.564% |
| Biovica International AB (publ) | -58.73 Million SEK | 77.477% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 70.743% |
| AcouSort AB (publ) | -23.98 Million SEK | 44.846% |
| Xintela AB (publ) | -7.8 Million SEK | -69.409% |
| Abliva AB (publ) | -57.24 Million SEK | 76.888% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 93.205% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 83.906% |
| OncoZenge AB (publ) | -12.62 Million SEK | -4.769% |
| Amniotics AB (publ) | -5.63 Million SEK | -134.893% |
| 2cureX AB (publ) | -13.4 Million SEK | 1.297% |
| CombiGene AB (publ) | -101.44 Million SEK | 86.959% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -512.179% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 344.985% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.865% |
| Corline Biomedical AB | -17.01 Million SEK | 22.236% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 84.203% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 90.424% |
| I-Tech AB | -83.26 Million SEK | 84.111% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 109.821% |
| Cyxone AB (publ) | -16.67 Million SEK | 20.641% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 76.328% |
| Biosergen AB | -1.88 Million SEK | -602.559% |
| Cantargia AB (publ) | -139.74 Million SEK | 90.533% |
| NextCell Pharma AB | -46.79 Million SEK | 71.727% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 89.784% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 54.977% |
| Nanologica AB (publ) | -9.38 Million SEK | -40.916% |
| SynAct Pharma AB | -61.75 Million SEK | 78.579% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 38.225% |
| LIDDS AB (publ) | -13.51 Million SEK | 2.093% |
| Lipum AB (publ) | -8.46 Million SEK | -56.281% |
| BioInvent International AB (publ) | -236.3 Million SEK | 94.402% |
| Alzinova AB (publ) | -21.22 Million SEK | 37.675% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 80.231% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -155.344% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 84.202% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1333.281% |
| Simris Alg AB (publ) | 85.07 Million SEK | 115.55% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 83.884% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 107.966% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 36.377% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -345.127% |